Peripherally Restricted Cannabinoid Compounds for Metabolic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hermansky-Pudlak Syndrome (HPS) associated pulmonary fibrosis lack effective therapeutic options, and CB1 receptor blockers like rimonabant cause neuropsychiatric side effects, limiting their therapeutic development.
Innovation Solution
Development of peripherally restricted cannabinoid receptor mediating compounds that selectively block CB1 receptors in peripheral tissues, minimizing brain penetration to avoid neuropsychiatric side effects, and concurrently inhibit inducible nitric oxide synthase (iNOS) to target fibrosis and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 receptor blocking drugs are used to treat obesity and metabolic syndrome, then therapeutic efficacy is improved, but neuropsychiatric side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective distribution properties - the compounds are engineered to concentrate in peripheral tissues (adipose tissue, liver, muscle) while minimizing penetration into the central nervous system. This spatial differentiation allows CB1 receptor blockade in peripheral organs without affecting brain CB1 receptors, thereby maintaining therapeutic efficacy for metabolic syndrome while avoiding neuropsychiatric side effects
Solution Approach 2:
The patent segments the therapeutic action by separating peripheral CB1 receptor blockade from central CB1 receptor interaction. By creating compounds that selectively target peripheral tissues, the therapeutic effect is segmented from the harmful neuropsychiatric effects that result from central nervous system penetration, allowing independent optimization of efficacy and safety
2Object-affected harmful factors
If peripherally restricted compounds are designed to minimize brain penetration, then neuropsychiatric side effects are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The compounds are designed with specific molecular properties that create local concentration gradients - high concentration in peripheral tissues where CB1 receptors mediate metabolic functions, and low concentration in the central nervous system. This localized action ensures therapeutic efficacy in target organs while minimizing harmful effects in the brain
Solution Approach 2:
The patent employs structural intermediaries - specific molecular scaffolds and substituent patterns - that act as mediators to control tissue distribution. These structural features serve as intermediaries between the pharmacophore and the tissue environment, directing the compound to peripheral tissues while preventing CNS penetration, thus maintaining therapeutic efficacy without neuropsychiatric side effects
3Adaptability or versatility
If dual-action compounds targeting both CB1 receptors and iNOS are developed, then therapeutic scope is expanded, but molecular complexity increases
Solution Approach 1:
The patent merges two distinct pharmacological activities - CB1 receptor blockade and iNOS inhibition - into single hybrid molecules. By combining the cannabinoid receptor-binding pharmacophore with iNOS inhibiting moieties, the compounds achieve dual therapeutic actions (metabolic regulation and anti-fibrotic effects) while maintaining manageable molecular complexity through strategic structural integration
Solution Approach 2:
The dual-action compounds exhibit multi-functionality by simultaneously targeting two different biological pathways - the endocannabinoid system and the nitric oxide synthase pathway. This universality allows a single compound to address multiple aspects of metabolic syndrome and fibrotic diseases, expanding therapeutic scope without requiring separate medications for each condition
Data Source
AI summary
A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold and (ii) a second therapeutic scaffold.